Kymera Therapeutics Inc (NASDAQ: KYMR) on Monday, soared 45.51% from the previous trading day, before settling in for the closing price of $29.64. Within the past 52 weeks, KYMR’s price has moved between $19.44 and $53.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 74.20%. The company achieved an average annual earnings per share of -19.92%. With a float of $53.22 million, this company’s outstanding shares have now reached $65.11 million.
The extent of productivity of a business whose workforce counts for 188 workers is very important to gauge. In terms of profitability, gross margin is 52.5%, operating margin of -472.5%, and the pretax margin is -409.07%.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kymera Therapeutics Inc is 18.27%, while institutional ownership is 95.95%. The most recent insider transaction that took place on May 23 ’25, was worth 75,436. In this transaction Chief Operating Officer of this company sold 2,575 shares at a rate of $29.30, taking the stock ownership to the 66,420 shares. Before that another transaction happened on May 23 ’25, when Company’s Officer proposed sale 2,575 for $30.17, making the entire transaction worth $77,688.
Kymera Therapeutics Inc (KYMR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -19.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.95% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Kymera Therapeutics Inc (KYMR) is currently performing well based on its current performance indicators. A quick ratio of 8.49 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.85 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
The latest stats from [Kymera Therapeutics Inc, KYMR] show that its last 5-days average volume of 1.98 million was superior to 0.72 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 68.44%. Additionally, its Average True Range was 2.85.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 91.57%, which indicates a significant decrease from 94.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 162.32% in the past 14 days, which was higher than the 95.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.40, while its 200-day Moving Average is $39.47. Now, the first resistance to watch is $45.78. This is followed by the second major resistance level at $48.42. The third major resistance level sits at $52.88. If the price goes on to break the first support level at $38.67, it is likely to go to the next support level at $34.21. The third support level lies at $31.57 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
Market capitalization of the company is 2.81 billion based on 65,120K outstanding shares. Right now, sales total 47,070 K and income totals -223,860 K. The company made 22,100 K in profit during its latest quarter, and -65,580 K in sales during its previous quarter.
